SARS-CoV 2 results of the total sample (N=2195) and the participant with self-reported vaccination data (n=2082) during the initial survey period 20 January 2021 to 30 April 21
| n (%) | |
| SARS-CoV-2 Results | 2195 |
| Negative results (<33.8 BAU/mL) | 1909 (87.0) |
| Positive results (≥33.8 BAU/mL) | 286 (13.0) |
| Participant with vaccination data | 2082 |
| Positive results by vaccination status | 269 |
| IgG+ and vaccinated (including only initial vaccination) | 160 (59.5) |
| IgG+ and unvaccinated | 109 (40.5) |
| Results split after initial vaccination | 149 |
| IgG− (<33.8 BAU/mL) | 32 (21.5) |
| IgG+ (≥33.8 BAU/mL) | 117 (78.5) |
| Results split after second vaccination | 43 |
| IgG− (<33.8 BAU/mL) | 0 (0.0) |
| IgG+ (≥33.8 BAU/mL) | 43 (100.0) |
| Results split according to positive PCR test results (only unvaccinated persons) | 83 |
| IgG− (<33.8 BAU/mL) | 8 (9.6) |
| IgG+ (≥33.8 BAU/mL) | 75 (90.4) |
| Results split by positive physician diagnosis of COVID-19 (unvaccinated only) | 64 |
| IgG− (<33.8 BAU/mL) | 8 (12.5) |
| IgG+ (≥33.8 BAU/mL) | 56 (87.5) |
BAU, binding antibody unit/mL.